Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects

Journal of Clinical Endocrinology and Metabolism

Volumn 73, Issue 6, 1991, Pages 1294-1301

  Defronzo, Ralph A ^a   Barzilai, Nir ^a   Simonson, Donald C ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A; METFORMIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE METABOLISM; HUMAN; LIVER METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, NON-INSULIN-DEPENDENT; FASTING; FEMALE; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN; LACTATES; LACTIC ACID; LIPIDS; LIVER; MALE; METFORMIN; MIDDLE AGE; OBESITY IN DIABETES; SUPPORT, NON-U.S. GOV'T;

EID: 0025837055     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jcem-73-6-1294     Document Type: Article

References (59)

1. Hermann LS. Metabolie effects of metformin in relation to clinical effects and side effects. In: Van der Kuy A, Hulst SGT, eds. Biguanide therapy today: Royal Society of Medicine. Int Congr Symp Ser 48. London: Academic Press; 1981;18.
2. Lucis OJ. The status of metformin in Canada. Can Med Assoc J. 1983;128:24-30.
3. Luft D, Schmulling RM, Eggstein M. Lactic acidosis in biguanide-treated diabetics. Diabetologia. 1978;14:75-87.
4. Searle GL, Siperstein MD. Lactic acidosis associated with phen-formin therapy: evidence that inhibited oxidation is the causative factor. Diabetes. 1975;24:741-5.
5. Cairns SA, Shalet S, Marshall AJ, Hartog M. A comparison of phenformin and metformin in the treatment of maturity onset diabetes. Diabetes Metab. 1977;3:183-8.
6. Clarke BF, Campbell IW. Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet. Br Med J. 1977;2:1576-8.
7. Jackson RA, Hawa MI, Jaspan JB, et al. Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes. 1987;36:632- 40.
8. U.K. Prospective Diabetes Study. II. Reduction in HbAlc with basal insulin supplement, sulfonylurea, or biguanide therapy in maturity-onset diabetes. Diabetes. 1985;34:793-8.
9. McBain AM, Brown IRF, Menzies DG, Campbell IW. Effects of improved glycaemic control on calcium and magnesium homeostasis in type II diabetes. J Clin Pathol. 1988;41:933-5.
10. Vigneri R, Goldfine ID. Role of metformin in treatment of diabetes mellitus. Diabetes Care. 1987;10:118-22.
11. Krall LP, Balodimos MC. Combined sulphonylurea-biguanide therapy of diabetes mellitus. In: Butterfield WJH, Westering V, eds. Tolbutamide after 10 years. Excerpta Medica, New York, NY Int Congr Ser 149. 1967;303-11.
12. Clarke BF, Duncan LFP. Combined metformin-chlorpropamide therapy in 108 diabetic suphonylurea failures. Lancet. 1965;1:1248- 51.
13. Higginbotham L, Martin FIR. Double-blind trial of metformin in therapy of non-ketotic diabetes. Med J Aust. 1979;2:154-6.
14. Czyzyk A, Lawecki J, Sadowski J, Ponikowksa I, Szczepanik Z. Effect of biguanides on intestinal absorption of glucose. Diabetes. 1968;17:492-8.
15. Gin H, Messerchnitt C, Brottier E, Aubertin J. Metformin improves insulin resistance in type I, insulin-dependent, diabetic patients. Metabolism. 1985;34:923-5.
16. Pagano G, Tagliaferro V, Carta Q, et al. Metformin reduces insulin requirement in type I (insulin-dependent) diabetes. Diabetologia. 1983;24:351-4.
17. Gin H, Slama G, Weissbrodt P, et al. Metformin reduces postprandial insulin needs in type I (insulin-dependent) diabetic patients: assessment by the artificial pancreas. Diabetologia. 1982;23:34-6.
18. Bailey CJ. Metformin revisisted: its actions and indications for use. Diabetic Med. 1988;5:315-20.
19. Bailey CJ, Puah JA. Effect of metformin on glucose metabolism in mouse soleus muscle. Diabetes Metab. 1986;12:212-8.
20. Lord JM, Puah JA, Atkins TW, Bailey CJ. Post-receptor effect of metformin on insulin action in mice. J Pharm Pharmacol. 1985;37:821-3.
21. Butterfield J, Fry IK, Holling E. Effects of insulin, tolbutamide, and phenethyldiguanidine on peripheral glucose uptake in man. Diabetes. 1958;7:449-54.
22. Nosadini R, Avogaro A, Trevisan R, et al. Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type 2 diabetes. Diabetes Care. 1989;10:62-7.
23. Wollen N, Bailey CJ. Inhibition of hepatic gluconeogenesis by metformin. Biochem Pharmacol. 1988;37:4353-8.
24. Cook DE, Blair JB, Lardy JA. Mode of action of hypoglycemic agents. V. Studies with phenethylbiguanide in isolated perfused rat liver. J Biol Chem. 1973;248:5272-7.
25. Haeckel R, Haeckel H. Inhibition of gluconeogenesis from lactate by phenethylbiguanide in the perfused guinea pig liver. Diabetolo-gia. 1982;7:117-24.
26. Karam JH, Matin SB, Forsham PH. Antidiabetic drugs after the University Group Diabetes Program (UGDP). Annu Rev Pharmacol. 1975;15:351-66.
27. Wu MS, Johnston P, Seu WHH, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes. Care. 1990;13:1-8.
28. Pezzino V, Trischitta V, Purrello F, Viguieri R. Effect of metformin on insulin binding to receptors in cultured human lymphocytes and breast cancer cells. Diabetologia. 1982;23:131-5.
29. Trischitta V, Gullo D, Pezzino V, Vignieri R. Metformin normalizes insulin binding to monocytes from obese nondiabetic subjects and obese type II diabetic patients. J Clin Endocrinol Metab. 1983;57:713-8.
30. Jacobs DB, Hayes GR, Truglia JA, Lockwood DH. Effects of metformin on insulin receptor tyrosine kinase activity in rat adipocytes. Diabetologia. 1987;29:798-801.
31. Prager R, Schenrthaner G. Insulin receptor binding to monocytes, insulin secretion, and glucose tolerance following metformin treatment: results of a double-blind cross-over study in type II diabetics. Diabetes. 1983;32:1083-6.
32. Purrello F, Gullo D, Brunetti A, et al. Direct effects of biguanides on glucose utilization in vitro. Metabolism. 1987;36:774-6.
33. Purrello F, Gullo D, Buscema M, Pejjino V, Vignieri R, Goldfine I. Metformin enhances certain insulin actions in cultured rat hepatoma cells. Diabetologia. 1988;31:385-9.
34. Fantus GI, Brosseau R. Mechanism of action of metformin: insulin receptor and post receptor effects in vitro and in vivo. J Clin Endocrinol Metab. 1986;63:898-905.
35. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method of quantifying insulin secretion and resistance. Am J Physiol. 1979;232:E214-23.
36. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP. The effect of insulin on the disposal of intravenous glucose: results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes. 1981;30:1000-7.
37. DeFronzo RA. The triumvirate: beta-cell, muscle, and liver. A collusion responsible for NIDDM. Diabetes. 1988;37:667-87.
38. Felber JP, Ferrannini E, Golay A, et al. Role of lipid oxidation in pathogenesis of insulin resistance of obesity and type II diabetes. Diabetes. 1987;36:1341-50.
39. Hales CN, Randle PJ. Immunoassay of insulin with insulin antibody precipitate. Biochem J. 1963;88:137-46.
40. Groop L, Bonadonna R, Del Prato S, et al. Glucose and free fatty acid metabolism in non-insulin dependent diabetes mellitus. J Clin Invest. 1989;84:205-13.
41. DeFronzo RA, Gunnarsson R, Bjorkman O, Olsson M, Wahren J. Effects of insulin on peripheral and splanchnic glucose metabolism in non-insulin dependent (type II) diabetes mellitus. J Clin Invest. 1985;76:149-55.
42. Tamborlane WV, Sherwin RS, Genel M, Felig P. Restoration of normal lipid and amino acid metabolism in diabetic patients treated with a portable insulin infusion pump. Lancet. 1979;1:1258-61.
43. Hawk PD. Kjeldahl method. In: Del Prato S, ed. Practical physiological chemistry, 12th ed. Toronto: Blakiston; 1947;814-22.
44. Charles BG, Jacobsen NW, Ravenscroft PJ. Rapid liquid chromatographic determination of metformin in plasma and urine. Clin Chem. 1981;27:434-6.
45. Radziuk J, Norwich KH, Vranic M. Measurements and validation of non-steady state turnover rates with application to the insulin and glucose systems. Fed Proc. 1974;33:1855-64.
46. Simonson DC, DeFronzo RA. Indirect calorimetry: methodological and interpretative problems. Am J Physiol. 1990;21:E399-412.
47. 3C nuclear magnetic resonance spectroscopy. N Engl J Med. 1990;322:223-8.
48. DeFronzo RA, Ferrannini E, Hendler R, Felig P, Wahren J. Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia. Diabetes. 1983;32:35-45.
49. Groop L, Luzi L, Melander A, et al. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and diabetic subjects. Diabetes. 1987;36:1320-8.
50. Simonson DC, Ferrannini E, Bevilacqua S, et al. Mechanism of improvement in glucose metabolism after chronic glyburide therapy. Diabetes. 1984;33:838-5.
51. Kolterman OG, Gray RS, Shapiro RG, Scarlett JA, Griffin J, Olefsky JM. The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. Diabetes. 1984;33:346-54.
52. Reaven G, Dray J. Effect of chlorpropamide on serum glucose and immunoreactive insulin concentrations in patients with maturity onset diabetes mellitus. Diabetes. 1967;16:487-92.
53. Fineberg SE, Schneider SH. Glipizide versus tolbutamide, an open trial. Effects on insulin secretory patterns and plasma concentrations. Diabetologia. 1980;18:49-54.
54. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism. 1989;38:387-95.
55. Henry RR, Wallace P, Olefsky JM. Effect of weight loss on mechanisms of hyperglycemia in obese non-insulin dependent diabetes mellitus. Diabetes. 1986;35:990-8.
56. Best JD, Judzewitsch RG, Pfeiffer MA, Beard JC, Halter JB, Porte D. The effect of chronic sulfonylurea treatment on hepatic glucose production in non-insulin dependent diabetes mellitus. Diabetes. 1982;21:333-8.
57. Bogardus C, Lillioja S, Howard BV, Reaven GR, Mott D. Relationships between insulin secretion, insulin action' and fasting plasma glucose concentration in nondiabetic and noninsulin dependent diabetic subjects. J Clin Invest. 1984;74:1238-46.
58. Prager R, Schernthaner G, Graf H. Effect of metformin on peripheral insulin sensitivity in non-insulin dependent diabetes mellitus. Diabetes Metab. 1985;11:346-50.
59. Cherrington AD, Stevenson RW, Steiner KE, et al. Insulin glucagon and glucose as regulators of hepatic glucose production in vivo. Diabetes Metab Rev. 1987;3:307-32